Brater DC, Harris C, Redfern JS, Gertz B. Renal effects of COX-2 inhibitors. Am J Nephrology 2001;21:1-15.
Excerpt link:
Based on this review of clinical evidence, it seems unlikely that COX-2 inhibitors (and perhaps their successors) will offer renal safety benefits over nonselective NSAID therapies.
Optimal pharmacotherapy to combat the atherogenic lipid triad.
Prescription for publication. How to submit patient or physician attitudinal survey data to medical journals.
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce residual cardiovascular risk.
The risks and hazards of interpreting and reporting health study measures. A simple, practical overview.
Renal effects of COX-2 inhibitors.
Public Awareness and Knowledge of Herpes Zoster: Results of a Global Survey.
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity
Healthy food and healthy choices: a new European profile approach.
Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine.
Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma.
Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes: Focus On Sitagliptin.
Caspofungin: an advanced treatment approach for suspected or confirmed invasive aspergillosis.
Managing hypertension in cardiology practice according to risk profile.
